Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid
NAGIOS: RODERIC FUNCIONANDO

Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid

DSpace Repository

Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid

Show simple item record

dc.contributor.author Marín Fernández, A.B. es
dc.contributor.author García Medina, Blas es
dc.contributor.author Aguilar Salvatierra, Antonio es
dc.contributor.author Jiménez Burkhardt, Alberto es
dc.contributor.author Gómez Moreno, Gerardo es
dc.date.accessioned 2015-09-21T08:57:22Z
dc.date.available 2015-09-21T08:57:22Z
dc.date.issued 2015 es
dc.identifier.uri http://hdl.handle.net/10550/47189
dc.source Marín Fernández, A.B. ; García Medina, Blas ; Aguilar Salvatierra, Antonio ; Jiménez Burkhardt, Alberto ; Gómez Moreno, Gerardo. Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid. En: Journal of Clinical and Experimental Dentistry, 2015, Vol. 7, No. 3: 444-446 es
dc.subject Odontología es
dc.subject Ciencias de la salud es
dc.title Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid es
dc.type info:eu-repo/semantics/article en
dc.type info:eu-repo/semantics/publishedVersion en
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.description.abstractenglish Bisphosphonates (BP) are a type of drug known to inhibit bone resorption through complex interventions. Their primary mechanism of action is aimed at the cellular level, inhibiting osteoclast activity and so bone resorption. BPs are widely used, with many patients receiving continuous treatment for years. But it is well known that these drugs can produce osteonecrosis of the jaw (ONJ). Zoledronic acid (ZA) is an intravenous BP used in the treatment and prophylaxis of bone disease in patients with malignant tumors with bone implication. ZA is the most potent BP in clinical development. This report describes the case of a 62-year-old woman with breast cancer antecedents which relapsed, who had received a maxillary dental implant two years before the start of therapy with zoledronic acid. She later developed osteonecrosis of the jaw (ONJ), which began in the peri-implant area, and was treated for stage 3 ONJ by sub-total maxillectomy es

View       (1.483Mb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics